These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10873747)
1. A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Fontaine V; van der Meijden E; de Graaf J; ter Schegget J; Struyk L Virology; 2000 Jun; 272(1):40-9. PubMed ID: 10873747 [TBL] [Abstract][Full Text] [Related]
2. In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation. Griffin BD; Moynagh PN Biochem J; 2006 Nov; 400(1):115-25. PubMed ID: 16792530 [TBL] [Abstract][Full Text] [Related]
3. A cell-type-specific transcription enhancer of type 16 human papillomavirus (HPV 16)-P97 promoter is defined with HPV-associated cellular events in human epithelial cell lines. Taniguchi A; Kikuchi K; Nagata K; Yasumoto S Virology; 1993 Aug; 195(2):500-10. PubMed ID: 8393236 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional activity of human papillomavirus type 31b enhancer is regulated through synergistic interaction of AP1 with two novel cellular factors. Kyo S; Tam A; Laimins LA Virology; 1995 Aug; 211(1):184-97. PubMed ID: 7645210 [TBL] [Abstract][Full Text] [Related]
5. Experimental analysis and computer prediction of CTF/NFI transcription factor DNA binding sites. Roulet E; Bucher P; Schneider R; Wingender E; Dusserre Y; Werner T; Mermod N J Mol Biol; 2000 Apr; 297(4):833-48. PubMed ID: 10736221 [TBL] [Abstract][Full Text] [Related]
6. Cooperative interaction of p65 and C/EBPbeta modulates transcription of BKV early promoter. Gorrill TS; Khalili K Virology; 2005 Apr; 335(1):1-9. PubMed ID: 15823601 [TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. Lee AH; Hong JH; Seo YS Biochem J; 2000 Aug; 350 Pt 1(Pt 1):131-8. PubMed ID: 10926836 [TBL] [Abstract][Full Text] [Related]
8. A distal element in the HPV-11 upstream regulatory region contributes to promoter repression in basal keratinocytes in squamous epithelium. Zhao W; Chow LT; Broker TR Virology; 1999 Jan; 253(2):219-29. PubMed ID: 9918880 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication. McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770 [TBL] [Abstract][Full Text] [Related]
10. Constitutive silencing of IFN-beta promoter is mediated by NRF (NF-kappaB-repressing factor), a nuclear inhibitor of NF-kappaB. Nourbakhsh M; Hauser H EMBO J; 1999 Nov; 18(22):6415-25. PubMed ID: 10562553 [TBL] [Abstract][Full Text] [Related]
11. NF-kappaB--a potential therapeutic target for inhibition of human cytomegalovirus (re)activation? Prösch S; Wuttke R; Krüger DH; Volk HD Biol Chem; 2002 Oct; 383(10):1601-9. PubMed ID: 12452437 [TBL] [Abstract][Full Text] [Related]
12. Transcription of the RelB gene is regulated by NF-kappaB. Bren GD; Solan NJ; Miyoshi H; Pennington KN; Pobst LJ; Paya CV Oncogene; 2001 Nov; 20(53):7722-33. PubMed ID: 11753650 [TBL] [Abstract][Full Text] [Related]
13. Overexpression and reactivation of binding activity of the recombinant CTF/NF-1 transcription factor. Amemiya K; Durham L; Major EO Protein Expr Purif; 1994 Feb; 5(1):57-64. PubMed ID: 8167474 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the infection-responsive bovine lactoferrin promoter. Zheng J; Ather JL; Sonstegard TS; Kerr DE Gene; 2005 Jun; 353(1):107-17. PubMed ID: 15935571 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma. Yan Y; Dalmasso G; Sitaraman S; Merlin D Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G535-45. PubMed ID: 17023546 [TBL] [Abstract][Full Text] [Related]
16. A biophysical characterisation of factors controlling dimerisation and selectivity in the NF-kappaB and NFAT families. de Lumley M; Hart DJ; Cooper MA; Symeonides S; Blackburn JM J Mol Biol; 2004 Jun; 339(5):1059-75. PubMed ID: 15178248 [TBL] [Abstract][Full Text] [Related]
17. Methylglyoxal suppresses TNF-alpha-induced NF-kappaB activation by inhibiting NF-kappaB DNA-binding. Laga M; Cottyn A; Van Herreweghe F; Vanden Berghe W; Haegeman G; Van Oostveldt P; Vandekerckhove J; Vancompernolle K Biochem Pharmacol; 2007 Aug; 74(4):579-89. PubMed ID: 17617381 [TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1. Zhou D; Masri S; Ye JJ; Chen S Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the epidermal growth factor receptor promoter: the effect of nuclear factor-kappaB. Nishi H; Neta G; Nishi KH; Akers LM; Rikiyama T; Proctor KN; Murphy BA; Johnson AC Int J Mol Med; 2003 Jan; 11(1):49-55. PubMed ID: 12469217 [TBL] [Abstract][Full Text] [Related]
20. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. Polzin RG; Benlhabib H; Trepel J; Herrera JE Gene; 2004 Oct; 341():209-18. PubMed ID: 15474303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]